BA
VRTX icon

Bridgewater Associates’s Vertex Pharmaceuticals VRTX Stock Holding History

Bridgewater Associates’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.96M Sell
13,357
-14,131
-51% -$6.59M 0.03% 379
2025
Q4 		$12.5M Sell
27,488
-10,836
-28% -$4.67M 0.05% 299
2025
Q3 		$15M Buy
38,324
+3,934
+11% +$1.64M 0.06% 253
2025
Q2 		$15.3M Buy
+34,390
New +$15.8M 0.06% 212
2025
Q1 		– Sell
-710
Closed -$286K – 806
2024
Q4 		$286K Sell
710
-2,742
-79% -$1.27M ﹤0.01% 634
2024
Q3 		$1.61M Sell
3,452
-29,777
-90% -$14.3M 0.01% 542
2024
Q2 		$15.6M Sell
33,229
-101,466
-75% -$44M 0.08% 187
2024
Q1 		$56.3M Buy
134,695
+2,341
+2% +$990K 0.28% 69
2023
Q4 		$53.9M Sell
132,354
-25,995
-16% -$9.6M 0.3% 65
2023
Q3 		$55.1M Sell
158,349
-17,964
-10% -$6.28M 0.33% 59
2023
Q2 		$62M Sell
176,313
-27,963
-14% -$9.42M 0.38% 54
2023
Q1 		$64.4M Buy
204,276
+103,457
+103% +$31M 0.39% 55
2022
Q4 		$29.1M Sell
100,819
-63,172
-39% -$19.3M 0.16% 119
2022
Q3 		$47.5M Sell
163,991
-53,161
-24% -$15.3M 0.24% 83
2022
Q2 		$61.2M Buy
217,152
+187,000
+620% +$50.1M 0.26% 80
2022
Q1 		$7.87M Buy
30,152
+17,735
+143% +$4.21M 0.03% 352
2021
Q4 		$2.73M Sell
12,417
-2,700
-18% -$525K 0.02% 420
2021
Q3 		$2.74M Sell
15,117
-8,139
-35% -$1.59M 0.02% 387
2021
Q2 		$4.69M Buy
23,256
+1,567
+7% +$328K 0.03% 341
2021
Q1 		$4.66M Buy
21,689
+18,059
+497% +$3.97M 0.04% 228
2020
Q4 		$858K Buy
+3,630
New +$833K 0.01% 405
2019
Q4 		– Sell
-32,260
Closed -$5.46M – 577
2019
Q3 		$5.46M Buy
+32,260
New +$5.71M 0.05% 137
2019
Q2 		– Sell
-21,889
Closed -$4.03M – 369
2019
Q1 		$4.03M Buy
+21,889
New +$4.04M 0.02% 155
2018
Q3 		– Sell
-15,509
Closed -$2.64M – 487
2018
Q2 		$2.64M Buy
+15,509
New +$2.4M 0.03% 181
2017
Q3 		– Sell
-18,673
Closed -$2.41M – 397
2017
Q2 		$2.41M Buy
+18,673
New +$2.25M 0.02% 156

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Bridgewater Associates's VRTX Position: Q1 2026 in Review

Bridgewater Associates reduced its Vertex Pharmaceuticals (VRTX) stake by 51% in Q1 2026, selling an estimated $6.59M and leaving 13,357 shares worth $5.96M. The position accounts for 0.03% of the portfolio, ranked #379.

Bridgewater Associates first reported a position in VRTX in Q2 2017 and has held it in 25 quarters since. The position peaked at $64.4M in Q1 2023. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Bridgewater Associates held 13,357 shares of Vertex Pharmaceuticals worth $5.96M as of Q1 2026.
  • Bridgewater Associates sold 14,131 Vertex Pharmaceuticals shares in Q1 2026, an estimated $6.59M.
  • Vertex Pharmaceuticals made up 0.03% of Bridgewater Associates's portfolio in Q1 2026, its #379 holding.
  • Bridgewater Associates first reported a position in Vertex Pharmaceuticals in Q2 2017 and has held it in 25 quarters since.
  • Bridgewater Associates's Vertex Pharmaceuticals position peaked at $64.4M in Q1 2023.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Bridgewater Associates's 13F filing for Q1 2026, filed 15 May 2026.